Investigating the mechanism of enhanced cytotoxicity of HPMA copolymer–Dox–AGM in breast cancer cells
Authors:
- Francesca GrecoFrancesca Greco
- María J. VicentMVMaría J. Vicent
- Siobhan GeeSGSiobhan Gee
- Arwyn T. JonesAJArwyn T. Jones
- Julia GeeJGJulia Gee
- Robert I. NicholsonRNRobert I. Nicholson
- Ruth DuncanRDRuth Duncan
- 1 January 2007
- journal article
- Published by Elsevier in Journal of Controlled Release
- Vol. 117 (1) , 28-39
Abstract
No abstract availableKeywords
This publication has 35 references indexed in Scilit:
- Polymer conjugates as anticancer nanomedicinesNature Reviews Cancer, 2006
- Polymer conjugates: nanosized medicines for treating cancerTrends in Biotechnology, 2006
- HPMA copolymer–aminoglutethimide conjugates inhibit aromatase in MCF-7 cell linesJournal of Drug Targeting, 2005
- Consensus StatementEndocrine-Related Cancer, 2005
- HPMA Copolymer-1,5-Diazaanthraquinone Conjugates as Novel Anticancer TherapeuticsJournal of Drug Targeting, 2004
- Size-dependent internalization of particles via the pathways of clathrin- and caveolae-mediated endocytosisBiochemical Journal, 2004
- The dawning era of polymer therapeuticsNature Reviews Drug Discovery, 2003
- Tamoxifen: a most unlikely pioneering medicineNature Reviews Drug Discovery, 2003
- The Ki-67 protein: From the known and the unknownJournal of Cellular Physiology, 2000
- Preclinical evaluation of polymer-bound doxorubicinJournal of Controlled Release, 1992